

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014529 A1(51) International Patent Classification: C07C 233/26,
C07D 209/40, 215/38, A61K 31/167, 31/47, 31/404, A61P
29/00KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.(21) International Application Number:
PCT/SE2004/001154

(22) International Filing Date: 28 July 2004 (28.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 8 August 2003 (08.08.2003) SE
0302192-0(71) Applicant (for all designated States except US): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors: and

(75) Inventors/Applicants (for US only): CLADINGBOEL,
David [GB/GB]; AstraZeneca R & D Chamwood,
Bakewell Road, Loughborough, Leicestershire LE11
5RH (GB). FORD, Rhona [GB/GB]; AstraZeneca R
& D Chamwood, Bakewell Road, Loughborough, Le-
icestershire LE11 5RH (GB). WILLIS, Paul [GB/GB];
AstraZeneca R & D Chamwood, Bakewell Road, Lough-
borough, Leicestershire LE11 5RH (GB).(74) Agent: ASTRAZENECA; Global Intellectual Property,
S-151 85 Södertälje (SE).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AR, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,(84) Designated States (unless otherwise indicated, for every
kind of national protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG)

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(52) Title: 2-ADAMANTYL DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS.

(57) Abstract: The invention provides compounds of formula (I) or a phar-
macologically acceptable salt or solvate or pro-drug thereof, wherein A, B,
X, n and m have the meanings as defined in the specification. Processes for
their preparation; pharmaceutical compositions containing them; and their
use in therapy are also described.

WO 2005/014529 A1